ALGEN Stock Overview
genOway Société anonyme, a biotechnology company, engages in the development and commercialization of custom genetically modified mouse, rat, and cell line models worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
genOway Société anonyme Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.94 |
| 52 Week High | €4.91 |
| 52 Week Low | €3.50 |
| Beta | 0.45 |
| 1 Month Change | -3.43% |
| 3 Month Change | -8.37% |
| 1 Year Change | 1.81% |
| 3 Year Change | 16.57% |
| 5 Year Change | 117.68% |
| Change since IPO | -34.44% |
Recent News & Updates
genOway Société anonyme's (EPA:ALGEN) Price Is Right But Growth Is Lacking
Jan 20
We Think genOway Société anonyme (EPA:ALGEN) Can Stay On Top Of Its Debt
Sep 27Recent updates
genOway Société anonyme's (EPA:ALGEN) Price Is Right But Growth Is Lacking
Jan 20We Think genOway Société anonyme (EPA:ALGEN) Can Stay On Top Of Its Debt
Sep 27We Think genOway Société anonyme (EPA:ALGEN) Has A Fair Chunk Of Debt
May 31We Think genOway Société anonyme (EPA:ALGEN) Has A Fair Chunk Of Debt
Nov 01Shareholder Returns
| ALGEN | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | 0% | 3.1% | 2.2% |
| 1Y | 1.8% | -9.1% | 3.2% |
Return vs Industry: ALGEN exceeded the French Biotechs industry which returned -9.1% over the past year.
Return vs Market: ALGEN underperformed the French Market which returned 3.2% over the past year.
Price Volatility
| ALGEN volatility | |
|---|---|
| ALGEN Average Weekly Movement | 3.9% |
| Biotechs Industry Average Movement | 6.7% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 9.6% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: ALGEN has not had significant price volatility in the past 3 months.
Volatility Over Time: ALGEN's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 124 | Alexandre Fraichard | www.genoway.com |
genOway Société anonyme, a biotechnology company, engages in the development and commercialization of custom genetically modified mouse, rat, and cell line models worldwide. It produces customized mouse models, such as knockout (KO) and knockin (KI) mouse models; customized rat models, including constitutive and conditional KO, point mutation KI, and quick KI rat models; and customized cell lines, such as constitutive and inducible KO, point mutation KI, reporter KI, quick KI, and KI cell lines. The company also offers humanized immune checkpoint mouse models; immunodeficient and reconstituted mouse and rat strains models; humanized immune target models; other mouse and rat catalog models; and cell lines.
genOway Société anonyme Fundamentals Summary
| ALGEN fundamental statistics | |
|---|---|
| Market cap | €35.50m |
| Earnings (TTM) | €1.57m |
| Revenue (TTM) | €20.05m |
22.6x
P/E Ratio1.8x
P/S RatioIs ALGEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALGEN income statement (TTM) | |
|---|---|
| Revenue | €20.05m |
| Cost of Revenue | €0 |
| Gross Profit | €20.05m |
| Other Expenses | €18.48m |
| Earnings | €1.57m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.17 |
| Gross Margin | 100.00% |
| Net Profit Margin | 7.82% |
| Debt/Equity Ratio | 47.5% |
How did ALGEN perform over the long term?
See historical performance and comparison